Sun Pharma and Incyte resolve their patent dispute, opening the door for the release of the anti-baldness medication LEQSELVI.
As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and other related patents.
India's largest pharmaceutical company, Sun Pharma announced on July 14 that it has settled a patent litigation with US biopharma MNC Incyte Corporation for an upfront payment over and above an ongoing royalty, paving the way for an immediate US launch of LEQSELVI (deuruxolitinib), used to treat severe alopecia areata, an autoimmune disease that leads to hair loss or baldness.
According to the agreement, all claims that were or may have been made in the ongoing LEQSELVI litigation will be jointly released, and both parties will request that the case be dismissed in the US District Court for the District of New Jersey.
A 'limited, non-exclusive license' to US Patent Nos. 9,662,335 and other related patents has been granted to Sun Pharma by Incyte as part of the arrangement. According to the announcement, this license covers oral deuruxolitinib for specific non-hematology-oncology applications that have been agreed upon, such as alopecia areata.
Sun Pharma will pay Incyte an upfront sum as well as continuing royalties until the patents expire in exchange for the settlement and license. The license agreement and settlement's precise financial parameters are kept under wraps.